Zobrazeno 1 - 10
of 363
pro vyhledávání: '"Jérôme Galon"'
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTIn the last decade, a plethora of immunotherapeutic strategies have been designed to modulate the tumor immune microenvironment. In particular, immune checkpoint (IC) blockade therapies present the most promising advances made in cancer treat
Externí odkaz:
https://doaj.org/article/09f80004c60e4f23ae689021c50d6ce1
Autor:
Fulong Wang, Shixun Lu, Di Cao, Juanjuan Qian, Cong Li, Rongxin Zhang, Feng Wang, Miaoqing Wu, Yifan Liu, Zhizhong Pan, Xiaojun Wu, Zhenhai Lu, Peirong Ding, Liren Li, Junzhong Lin, Aurélie Catteau, Jérôme Galon, Gong Chen
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTThis study aimed to validate the prognostic value of Immunoscore (IS) in stage II colorectal cancer (CRC), and explore the roles of IS and circulating tumor DNA (ctDNA) in the adjuvant treatment for early-stage CRC. Resected tumor samples fro
Externí odkaz:
https://doaj.org/article/89b95f1a4dbf4a6e976c2cbd1aeac50d
Autor:
Paolo A. Ascierto, Sanjiv S. Agarwala, Allison Betof Warner, Marc S. Ernstoff, Bernard A. Fox, Thomas F. Gajewski, Jérôme Galon, Claus Garbe, Brian R. Gastman, Jeffrey E. Gershenwald, Pawel Kalinski, Michelle Krogsgaard, Rom S. Leidner, Roger S. Lo, Alexander M. Menzies, Olivier Michielin, Poulikos I. Poulikakos, Jeffrey S. Weber, Corrado Caracò, Iman Osman, Igor Puzanov, Magdalena Thurin
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-17 (2023)
Abstract Outcomes for patients with melanoma have improved over the past decade with the clinical development and approval of immunotherapies targeting immune checkpoint receptors such as programmed death-1 (PD-1), programmed death ligand 1 (PD-L1) o
Externí odkaz:
https://doaj.org/article/06bb97ac823040b3bb11134f118a0c11
Publikováno v:
Cancers, Vol 16, Iss 9, p 1686 (2024)
(1) Background: Digital pathology (DP) is transforming the landscape of clinical practice, offering a revolutionary approach to traditional pathology analysis and diagnosis. (2) Methods: This innovative technology involves the digitization of traditi
Externí odkaz:
https://doaj.org/article/452e342ba9a744078be02e94fbbac004
Autor:
François Ghiringhelli, Frederic Bibeau, Laurent Greillier, Jean-David Fumet, Alis Ilie, Florence Monville, Caroline Laugé, Aurélie Catteau, Isabelle Boquet, Amine Majdi, Erwan Morgand, Youssef Oulkhouir, Nicolas Brandone, Julien Adam, Thomas Sbarrato, Alboukadel Kassambara, Jacques Fieschi, Stéphane Garcia, Anne Laure Lepage, Pascale Tomasini, Jérôme Galon
Publikováno v:
EBioMedicine, Vol 92, Iss , Pp 104633- (2023)
Summary: Background: Anti-PD-1 and PD-L1 antibodies (mAbs) are approved immunotherapy agents to treat metastatic non-small cell lung cancer (NSCLC) patients. Only a minority of patients responds to these treatments and biomarkers predicting response
Externí odkaz:
https://doaj.org/article/af4bad0461854aff8dc0c5518a34fcbc
Autor:
Assia Hijazi, Jérôme Galon
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
ABSTRACTIn clinical practice, the administration of adjuvant chemotherapy (ACT) following tumor surgical resection raises a critical dilemma for stage II colon cancer (CC) patients. The prognostic features used to identify high-risk CC patients rely
Externí odkaz:
https://doaj.org/article/002c5f66765d4ba698be57bc55cd3acf
Autor:
Paolo A. Ascierto, Antonio Avallone, Nina Bhardwaj, Carlo Bifulco, Sergio Bracarda, Joshua D. Brody, Luigi Buonaguro, Sandra Demaria, Leisha A. Emens, Robert L. Ferris, Jérôme Galon, Samir N. Khleif, Christopher A. Klebanoff, Tamara Laskowski, Ignacio Melero, Chrystal M. Paulos, Sandro Pignata, Marco Ruella, Inge Marie Svane, Janis M. Taube, Bernard A. Fox, Patrick Hwu, Igor Puzanov
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-19 (2022)
Abstract Over the past decade, immunotherapy has become an increasingly fundamental modality in the treatment of cancer. The positive impact of immune checkpoint inhibition, especially anti-programmed death (PD)-1/PD-ligand (L)1 blockade, in patients
Externí odkaz:
https://doaj.org/article/c7c0a3307fce4f8da5d3d700a08bd2c5
Autor:
Joseph Willis, Robert A. Anders, Toshihiko Torigoe, Yoshihiko Hirohashi, Carlo Bifulco, Inti Zlobec, Bernhard Mlecnik, Sandra Demaria, Won-Tak Choi, Pavel Dundr, Fabiana Tatangelo, Annabella Di Mauro, Pamela Baldin, Gabriela Bindea, Florence Marliot, Nacilla Haicheur, Tessa Fredriksen, Amos Kirilovsky, Bénédicte Buttard, Angela Vasaturo, Lucie Lafontaine, Pauline Maby, Carine El Sissy, Assia Hijazi, Amine Majdi, Christine Lagorce, Anne Berger, Marc Van den Eynde, Franck Pagès, Alessandro Lugli, Jérôme Galon
Publikováno v:
Cancers, Vol 15, Iss 16, p 4045 (2023)
Background: The Immunoscore (IS) is a quantitative digital pathology assay that evaluates the immune response in cancer patients. This study reports on the reproducibility of pathologists’ visual assessment of CD3+- and CD8+-stained colon tumors, c
Externí odkaz:
https://doaj.org/article/7426d03a66c4425eabc9e6f970f30903
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The complex dynamics of the tumor-immune interaction during tumor progression have been characterized by integrating genomic and proteomic experiments. The Immunome, a reference compendium of markers for the majority of immune cell subpopulations was
Externí odkaz:
https://doaj.org/article/1003a25309c44ef09de568e3f5a1b45f
Autor:
Alessandro Ottaiano, Mariachiara Santorsola, Luisa Circelli, Anna Maria Trotta, Francesco Izzo, Francesco Perri, Marco Cascella, Francesco Sabbatino, Vincenza Granata, Marco Correra, Luca Tarotto, Salvatore Stilo, Francesco Fiore, Nicola Martucci, Antonello La Rocca, Carmine Picone, Paolo Muto, Valentina Borzillo, Andrea Belli, Renato Patrone, Edoardo Mercadante, Fabiana Tatangelo, Gerardo Ferrara, Annabella Di Mauro, Giosué Scognamiglio, Massimiliano Berretta, Maurizio Capuozzo, Angela Lombardi, Jérôme Galon, Oreste Gualillo, Ugo Pace, Paolo Delrio, Giovanni Savarese, Stefania Scala, Guglielmo Nasti, Michele Caraglia
Publikováno v:
Cancers, Vol 15, Iss 6, p 1827 (2023)
Some cancer patients display a less aggressive form of metastatic disease, characterized by a low tumor burden and involving a smaller number of sites, which is referred to as “oligometastatic disease” (OMD). This review discusses new biomarkers,
Externí odkaz:
https://doaj.org/article/a58da5d9414f42f494999e374ef20e28